CN114901697A - 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 - Google Patents
一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 Download PDFInfo
- Publication number
- CN114901697A CN114901697A CN202180007833.9A CN202180007833A CN114901697A CN 114901697 A CN114901697 A CN 114901697A CN 202180007833 A CN202180007833 A CN 202180007833A CN 114901697 A CN114901697 A CN 114901697A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 52
- 102000036639 antigens Human genes 0.000 title claims abstract description 52
- 108091007433 antigens Proteins 0.000 title claims abstract description 52
- 230000027455 binding Effects 0.000 title claims abstract description 51
- 239000012634 fragment Substances 0.000 title claims abstract description 43
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 102000017578 LAG3 Human genes 0.000 claims abstract description 52
- 101150030213 Lag3 gene Proteins 0.000 claims abstract description 49
- 208000026278 immune system disease Diseases 0.000 claims abstract description 17
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 14
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims abstract description 8
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims abstract description 8
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims abstract description 8
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 8
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 8
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims abstract description 8
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 8
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 8
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 8
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 8
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 8
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 8
- 208000032839 leukemia Diseases 0.000 claims abstract description 8
- 201000007270 liver cancer Diseases 0.000 claims abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 201000005202 lung cancer Diseases 0.000 claims abstract description 8
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 8
- 201000001441 melanoma Diseases 0.000 claims abstract description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 8
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 152
- 241001529936 Murinae Species 0.000 claims description 67
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 229960003301 nivolumab Drugs 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 abstract description 7
- 101001081189 Homo sapiens Rho GTPase-activating protein 45 Proteins 0.000 description 30
- 102100027748 Rho GTPase-activating protein 45 Human genes 0.000 description 30
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 239000013598 vector Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000010171 animal model Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 241001463139 Vitta Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000002733 pharmacodynamic assay Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
涉及生物医药领域,具体提供了一种抗LAG‑3的单克隆抗体、其抗原结合片段及其应用,其包括重链可变区和轻链可变区,单克隆抗体或其抗原结合片段选自A‑1、A‑2、A‑3、A‑4中任意一种。提供的单克隆抗体能够特异性结合LAG‑3,亲和力较高,且具有很好的生物学活性,能够用于治疗多种癌症或者免疫疾病,癌症包括白血病、肺癌、胃癌、食道癌、卵巢癌、头颈癌、黑色素瘤、肾癌、乳腺癌、结直肠癌、肝癌、胰腺癌或膀胱癌,免疫疾病包括银屑病、克罗恩病、类风湿性关节炎、原发性胆汁性肝硬化、系统性红斑狼疮、多发性硬化症、溃疡性结肠炎和自身免疫性肝炎。
Description
PCT国内申请,说明书已公开。
Claims (18)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020114365815 | 2020-12-10 | ||
CN202011436581.5A CN114621345B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
PCT/CN2021/133941 WO2022121720A1 (zh) | 2020-12-10 | 2021-11-29 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114901697A true CN114901697A (zh) | 2022-08-12 |
CN114901697B CN114901697B (zh) | 2022-12-13 |
Family
ID=81895398
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211155535.7A Active CN116514971B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202211155576.6A Active CN115819585B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202011436581.5A Active CN114621345B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202211155539.5A Active CN116514972B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202180007833.9A Active CN114901697B (zh) | 2020-12-10 | 2021-11-29 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211155535.7A Active CN116514971B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202211155576.6A Active CN115819585B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202011436581.5A Active CN114621345B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN202211155539.5A Active CN116514972B (zh) | 2020-12-10 | 2020-12-10 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240025994A1 (zh) |
EP (1) | EP4242234A1 (zh) |
JP (1) | JP2023552621A (zh) |
KR (1) | KR20230118922A (zh) |
CN (5) | CN116514971B (zh) |
AU (1) | AU2021398061A1 (zh) |
CA (1) | CA3204858A1 (zh) |
IL (1) | IL303443A (zh) |
WO (1) | WO2022121720A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115819585A (zh) * | 2020-12-10 | 2023-03-21 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN115869399A (zh) * | 2022-12-28 | 2023-03-31 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用 |
CN116199779A (zh) * | 2022-12-08 | 2023-06-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017219995A1 (zh) * | 2016-06-23 | 2017-12-28 | 江苏恒瑞医药股份有限公司 | Lag-3抗体、其抗原结合片段及其医药用途 |
US20180127499A1 (en) * | 2016-10-11 | 2018-05-10 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
CN109475617A (zh) * | 2017-02-22 | 2019-03-15 | 天境生物 | 抗lag-3抗体及其应用 |
WO2020173378A1 (zh) * | 2019-02-28 | 2020-09-03 | 三生国健药业(上海)股份有限公司 | 结合人lag-3的抗体、其制备方法和用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103525868B (zh) | 2013-10-17 | 2015-01-21 | 百泰生物药业有限公司 | 哺乳动物细胞高效表达载体的构建及应用 |
BR112016017174A2 (pt) * | 2014-01-28 | 2017-10-03 | Bristol Myers Squibb Co | Anticorpos anti-lag-3 para tratar malignidades hematológicas |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
IL268527B2 (en) * | 2017-04-05 | 2024-03-01 | Hoffmann La Roche | Bispecific antibodies bind to PD1 and LAG3 specifically |
CN111542546B (zh) * | 2018-01-18 | 2022-08-16 | 四川科伦博泰生物医药股份有限公司 | 抗lag-3抗体及其用途 |
CN110305215B (zh) * | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
CN110606892B (zh) * | 2018-06-14 | 2023-09-26 | 华博生物医药技术(上海)有限公司 | 一种高亲和力高生物活性的lag-3抗体及其应用 |
CN116514971B (zh) * | 2020-12-10 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN114617961B (zh) * | 2020-12-10 | 2022-12-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3单克隆抗体的注射制剂 |
CN114621344B (zh) * | 2020-12-10 | 2022-08-30 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3单克隆抗体的纯化方法 |
-
2020
- 2020-12-10 CN CN202211155535.7A patent/CN116514971B/zh active Active
- 2020-12-10 CN CN202211155576.6A patent/CN115819585B/zh active Active
- 2020-12-10 CN CN202011436581.5A patent/CN114621345B/zh active Active
- 2020-12-10 CN CN202211155539.5A patent/CN116514972B/zh active Active
-
2021
- 2021-11-29 AU AU2021398061A patent/AU2021398061A1/en active Pending
- 2021-11-29 CA CA3204858A patent/CA3204858A1/en active Pending
- 2021-11-29 JP JP2023535502A patent/JP2023552621A/ja active Pending
- 2021-11-29 IL IL303443A patent/IL303443A/en unknown
- 2021-11-29 EP EP21902427.0A patent/EP4242234A1/en active Pending
- 2021-11-29 KR KR1020237023286A patent/KR20230118922A/ko active Search and Examination
- 2021-11-29 WO PCT/CN2021/133941 patent/WO2022121720A1/zh active Application Filing
- 2021-11-29 CN CN202180007833.9A patent/CN114901697B/zh active Active
- 2021-11-29 US US18/039,720 patent/US20240025994A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017219995A1 (zh) * | 2016-06-23 | 2017-12-28 | 江苏恒瑞医药股份有限公司 | Lag-3抗体、其抗原结合片段及其医药用途 |
US20180127499A1 (en) * | 2016-10-11 | 2018-05-10 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
CN110023337A (zh) * | 2016-10-11 | 2019-07-16 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
CN109475617A (zh) * | 2017-02-22 | 2019-03-15 | 天境生物 | 抗lag-3抗体及其应用 |
WO2020173378A1 (zh) * | 2019-02-28 | 2020-09-03 | 三生国健药业(上海)股份有限公司 | 结合人lag-3的抗体、其制备方法和用途 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115819585A (zh) * | 2020-12-10 | 2023-03-21 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN115819585B (zh) * | 2020-12-10 | 2023-06-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
CN116199779A (zh) * | 2022-12-08 | 2023-06-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 |
CN116199779B (zh) * | 2022-12-08 | 2023-08-11 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 |
CN115869399A (zh) * | 2022-12-28 | 2023-03-31 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2021398061A9 (en) | 2023-08-24 |
CN116514971B (zh) | 2023-10-27 |
KR20230118922A (ko) | 2023-08-14 |
CN116514972A (zh) | 2023-08-01 |
AU2021398061A1 (en) | 2023-07-20 |
WO2022121720A1 (zh) | 2022-06-16 |
CN116514972B (zh) | 2023-10-27 |
US20240025994A1 (en) | 2024-01-25 |
EP4242234A1 (en) | 2023-09-13 |
CN115819585A (zh) | 2023-03-21 |
JP2023552621A (ja) | 2023-12-18 |
CA3204858A1 (en) | 2022-06-16 |
CN115819585B (zh) | 2023-06-02 |
IL303443A (en) | 2023-08-01 |
CN114901697B (zh) | 2022-12-13 |
CN114621345B (zh) | 2022-11-29 |
CN114621345A (zh) | 2022-06-14 |
CN116514971A (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114901697B (zh) | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 | |
CN110964111B (zh) | 一种抗pd-l1单克隆抗体、其抗原结合片段及其应用 | |
CN109776678A (zh) | 一种人源化pd-l1单克隆抗体、其制备方法和应用 | |
CN110655579B (zh) | 一种新型抗ctla-4单克隆抗体及其应用 | |
CN107840885B (zh) | Gm-csf抗体及其用途 | |
WO2024022008A1 (zh) | 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用 | |
CN114621344B (zh) | 一种抗lag-3单克隆抗体的纯化方法 | |
CN114617961B (zh) | 一种抗lag-3单克隆抗体的注射制剂 | |
CN113402607A (zh) | 一种抗lap单克隆抗体、其抗原结合片段及其应用 | |
CN107840886B (zh) | Gm-csf抗体及其用途 | |
CN116199779B (zh) | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 | |
CN117447593B (zh) | 一种抗Siglec-15单克隆抗体 | |
CN117447594B (zh) | 一种抗Siglec-15单克隆抗体 | |
CN117447595B (zh) | 一种抗Siglec-15单克隆抗体 | |
CN117447592B (zh) | 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用 | |
US20230159652A1 (en) | Transferrin receptor 1 targeting for carcinogenesis prevention | |
CN115819587A (zh) | 一种抗nkg2a单克隆抗体及其应用 | |
CN115947850A (zh) | 一种靶向lilrb4的单克隆抗体 | |
CN116284393A (zh) | 一种靶向lilrb4的单克隆抗体 | |
CN118243802A (zh) | 一种抗Siglec-15单克隆抗体电荷异质性的检测方法 | |
CN116178550A (zh) | 一种抗lilrb4单克隆抗体 | |
CN116143922A (zh) | 一种抗lilrb4单克隆抗体 | |
CN116023498A (zh) | 一种抗lilrb4单克隆抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |